Iovance Biotherapeutics (NASDAQ:IOVA) Issues Earnings Results

Iovance Biotherapeutics (NASDAQ:IOVA) posted its earnings results on Thursday. The biotechnology company reported ($0.26) EPS for the quarter, hitting the consensus estimate of ($0.26), Zacks reports. Iovance Biotherapeutics had a negative net margin of 451.25% and a negative return on equity of 58.43%. Iovance Biotherapeutics updated its FY 2025 guidance to EPS.

Iovance Biotherapeutics Stock Performance

Shares of NASDAQ:IOVA opened at $5.26 on Friday. The stock’s 50-day moving average is $6.27 and its 200-day moving average is $8.62. The company has a market cap of $1.60 billion, a P/E ratio of -3.53 and a beta of 0.53. Iovance Biotherapeutics has a 52-week low of $5.05 and a 52-week high of $18.33.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on IOVA. HC Wainwright reiterated a “buy” rating and issued a $32.00 price objective on shares of Iovance Biotherapeutics in a report on Friday. Piper Sandler decreased their price target on Iovance Biotherapeutics from $7.50 to $6.00 and set a “neutral” rating for the company in a research note on Friday. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, Iovance Biotherapeutics presently has an average rating of “Moderate Buy” and an average target price of $20.86.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.